Street View: India's Sun Pharma rises after U.S. tariff reprieve tied to drug-pricing deal
BUZZ-Street View: India's Sun Pharma rises after U.S. tariff reprieve tied to drug-pricing deal ** Sun Pharmaceutical Industries SUN.NS secures two-year delay to potential U.S. tariffs on its innovative drugs by agreeing to offer discounted medicines to Medicaid patients
** Shares of the company were up 0.5% to 1,938 rupees
TARIFF REPRIEVE OUTWEIGHING MEDICAID PRICING IMPACT
** Bernstein ("Outperform," PT: 2,235 rupees) says agreement removes a near-term margin overhang and supports Sun's innovation-led pipeline through global partnerships
** HSBC Global Investment Research ("Buy," PT: 2,120 rupees)sees improving profitability of Sun's innovative medicines portfolio boosting operating leverage and consolidated margins
** Kotak Institutional Equities ("Add," PT: 2,150 rupees) says lower Medicaid pricing could weigh on EPS, but Medicare exclusion and tariff reprieve make the deal marginally positive
** ICICI Securities ("Add," PT: 2,100 rupees) says tariff protection safeguards Sun's specialty portfolio, though similar protection is needed for Organon after the acquisition
"The deal may also help Sun win M&A deals, especially for companies and assets at risk of being hit by tariffs," - ICICI
(Reporting by Abhinav Parmar in Bengaluru)
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses